donepezil hydrochloride - Profile

What are the generic sources for donepezil hydrochloride and what is the scope of freedom to operate?

Donepezil hydrochloride is the generic ingredient in six branded drugs marketed by Eisai Inc, Corium, Aiping Pharm Inc, Chartwell Rx, Hisun Pharm Hangzhou, Macleods Pharms Ltd, Sun Pharm Industries, Unichem, Zydus Pharms Usa Inc, Accord Hlthcare, Actavis Elizabeth, Alembic Pharms Ltd, Apotex, Aurobindo, Cadila Pharms Ltd, Cipla Ltd, Dexcel, Dr Reddys, Dr Reddys Labs Ltd, Heritage Pharma, Hetero Labs Ltd V, Hikma Pharms, Indicus Pharma, Jubilant Generics, Lupin, Natco Pharma, Novitium Pharma, Osmotica Pharm Us, Ph Health, Prinston Inc, Rising, Sciegen Pharms, Strides Pharma, Sun Pharm, Sun Pharm Inds, Sun Pharm Inds Ltd, Torrent Pharms, Twi Pharms, Wockhardt, Zydus Lifesciences, Zydus Pharms, Amneal, Ani Pharms, Xiamen Lp Pharm Co, and Abbvie, and is included in fifty-seven NDAs. There are fourteen patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Donepezil hydrochloride has one hundred and twenty-eight patent family members in sixteen countries.

There are two tentative approvals for this compound.

Summary for donepezil hydrochloride

International Patents:	128
US Patents:	14
Tradenames:	6
Applicants:	45
NDAs:	57
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for donepezil hydrochloride

Generic filers with tentative approvals for DONEPEZIL HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		10MG	TABLET; ORAL
		5MG	TABLET; ORAL
		10MG;21MG	CAPSULE, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for DONEPEZIL HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ARICEPT	Tablets	donepezil hydrochloride	23 mg	022568		2013-07-09
ARICEPT ODT	Orally Disintegrating Tablets	donepezil hydrochloride	5 mg and 10 mg	021720	1	2010-06-30

US Patents and Regulatory Information for donepezil hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eisai Inc	ARICEPT	donepezil hydrochloride	SOLUTION;ORAL	021719-001	Oct 18, 2004		DISCN	Yes	No
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-001	Mar 11, 2022		DISCN	Yes	No	12,161,767		Y	Y
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-001	Mar 11, 2022		DISCN	Yes	No	12,168,075
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-001	Mar 11, 2022		DISCN	Yes	No	11,648,214		Y
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-001	Mar 11, 2022		DISCN	Yes	No	10,966,936		Y
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-001	Mar 11, 2022		DISCN	Yes	No	11,103,463
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-001	Mar 11, 2022		DISCN	Yes	No	10,835,499		Y

Expired US Patents for donepezil hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eisai Inc	ARICEPT ODT	donepezil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021720-002	Oct 18, 2004	4,895,841
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-001	Nov 25, 1996	6,245,911
Eisai Inc	ARICEPT ODT	donepezil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021720-002	Oct 18, 2004	7,727,552
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-002	Nov 25, 1996	4,895,841
Eisai Inc	ARICEPT ODT	donepezil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021720-001	Oct 18, 2004	4,895,841
Eisai Inc	ARICEPT ODT	donepezil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021720-002	Oct 18, 2004	7,727,548
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-002	Nov 25, 1996	6,245,911

International Patents for donepezil hydrochloride

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006070781
Japan	7153010
South Korea	102406536
South Korea	102406528
Australia	2017302306
Japan	7071330
Japan	2019525932

Supplementary Protection Certificates for donepezil hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0296560	2/1998	Austria		PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214
0296560	SPC/GB97/023	United Kingdom		PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214

Donepezil Hydrochloride: Investment Scenario and Fundamentals Analysis

Last updated: February 20, 2026

What Is the Market Landscape for Donepezil Hydrochloride?

Donepezil hydrochloride is a cholinesterase inhibitor approved primarily for Alzheimer’s disease (AD). It has a long approval history, with initial US FDA approval in 1996. The drug’s global market size was valued at approximately $3.3 billion in 2022, with projections reaching $4.5 billion by 2030, growing at a compound annual growth rate (CAGR) of near 4.2% (Fortune Business Insights, 2023).

While generic availability has increased since patent expiry in 2016, branded formulations maintain higher margins in certain markets due to branding and formulary preferences. The drug’s primary competitors are rivastigmine and galantamine, though donepezil holds a significant share based on efficacy and tolerability profiles.

What Are the Key Regulatory and Patent Dynamics?

Donepezil hydrochloride was originally patented by Eisai and Pfizer, with patent protections expiring around 2016. Despite generic competition, some formulations or delivery methods retain exclusivity in specific regions due to secondary patents or formulation patents. For instance:

• Pfizer’s patent on the formulation expired in major markets by 2016.
• Some regional secondary patents or exclusivities extend commercial viability for specific formulations, especially in regions with delayed patent challenges.

In terms of regulatory landscape, donepezil remains on the WHO Essential Medicines List, with continued approvals across multiple jurisdictions. No recent significant patent litigation or exclusivity extensions have been announced.

How Is the R&D Environment Shaping the Future?

Current R&D efforts focus on disease modification, combination therapies, and improving tolerability and adherence. Key pipeline candidates include:

• Biomarker-driven therapies for early detection.
• Donepezil derivatives with improved bioavailability and reduced side effects.
• Combination regimens pairing donepezil with NMDA receptor antagonists or monoclonal antibodies targeting amyloid plaques.

While no new formulations are near approval, ongoing research supports sustained interest due to the persistent unmet need in Alzheimer’s treatment.

What Are the Market Drivers and Challenges?

Drivers:

• Increasing prevalence of Alzheimer’s disease, expected to reach 152 million cases worldwide by 2050.
• Aging populations in North America, Europe, and Asia.
• Established efficacy and safety profile of donepezil, fostering prescriber confidence.

Challenges:

• Competition from newer agents, including disease-modifying drugs like aducanumab.
• Patent expirations leading to price erosion.
• Regulatory shifts favoring personalized medicine and targeted therapies.
• Limited current options for disease modification, promoting incremental approaches like donepezil.

Financial Fundamentals and Investment Opportunities

Revenue Streams

• Legacy sales from existing formulations.
• Premium formulations or combination products.
• Licensing or partnerships with generic manufacturers.

Cost Structure

• R&D investments are modest, focused on incremental improvements.
• Manufacturing costs are relatively low; chemical synthesis is established.
• Regulatory costs shift toward post-marketing surveillance, especially for new delivery methods.

Profitability Outlook

• Margins reflect market share retention, with branded drugs earning higher margins.
• Price erosion from generics affects revenue but can be offset by volume growth.
• Portfolio diversification into combination therapies presents upside.

Licensing and Market Expansion

• Outlicensed formulations in emerging markets.
• Collaborations for biomarker-based diagnostic tools.
• Entry into markets where Alzheimer’s prevalence is rising fastest, such as China and India.

Competitive Positioning

• High familiarity among prescribers.
• Cost-effectiveness in comparison to newer therapies.
• Increasing focus on early-stage intervention supports sustained demand.

Entry Barriers

• Regulatory approvals for new formulations.
• Patent challenges for secondary patents.
• Established competitive landscape with multiple generics.

Risk Factors

• Patent litigation and generic price cuts.
• Regulatory hurdles for combination therapies.
• Market shifts toward alternative therapies with disease-modifying claims.

Conclusions

Investing in donepezil hydrochloride offers exposure to the mature Alzheimer’s treatment market with stable revenues, though growth prospects hinge on incremental innovation and geographic expansion. The aging global population supports continued demand, but intense generic competition and patent expiries dampen valuation upside. Strategic partnerships and pipeline innovations can mitigate risks and unlock new revenue streams.

---

Key Takeaways

• The donepezil market is mature, with global sales expected to grow modestly by 4.2% annually.
• Patent expiry in 2016 shifted focus toward generics, but branded versions retain value through formulation-specific patents and regional exclusivities.
• R&D is focused on combination therapies, drug delivery improvements, and biomarkers for early diagnosis.
• Key risks include patent challenges, generic price erosion, and competition from newer therapies.
• Investment potential lies in market expansion, licensing, and incremental R&D innovations.

---

FAQs

1. How long does donepezil hydrochloride’s patent protection last?
Patent protections generally expired around 2016 in many regions, leading to a surge in generic competition.

2. Are there any new formulations or delivery methods in development?
Yes, research aims at formulations with improved bioavailability, reduced side effects, or as part of combination therapy approaches, but none have reached late-stage approval.

3. What is the outlook for generic vs. branded sales?
Generic sales dominate volumes but offer lower margins. Branded formulations maintain higher profitability where patent protections or formulations provide exclusivity.

4. How might pipeline therapies impact the donepezil market?
While newer agents with disease-modifying mechanisms threaten to displace symptomatic drugs, donepezil’s entrenched market position offers resilience, especially in combination therapies.

5. Which regions present the best growth opportunities?
Emerging markets such as China and India, with rising AD prevalence, offer substantial growth prospects due to increasing healthcare investment and aging populations.

---

References

1. Fortune Business Insights. (2023). Alzheimer’s Disease Market Size, Share & Industry Analysis. Retrieved from https://www.fortunebusinessinsights.com
2. U.S. Food and Drug Administration. (2016). Patent expiration date for donepezil hydrochloride.
3. WHO. (2022). WHO Model List of Essential Medicines, 22nd Edition.
4. Market research reports on Alzheimer’s therapeutics and pipeline overview.